News about Global Pharma

Eton Pharmaceuticals Announces Acquisition of Galzin

Galzin is FDA-approved as a maintenance treatment of patients with Wilson Disease who have been initially treated with a chelating agent.

Global Pharma | 04/01/2025 | By Aishwarya |  381

Pharmanovia Signs In-Licensing Deal for Osteoporosis Treatment with Radius Health

Under the terms of the agreement Pharmanovia will be responsible for clinical, regulatory and commercial activities across key markets in the Asia Pacific region, specifically China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines.

Global Pharma | 04/01/2025 | By Aishwarya |  1069

Venus Remedies Secures GMP Certification for Antibiotic-Carbapenem Facility in Moldova

Venus Remedies has received GMP certification from the Ministry of Health of Moldova for its antibiotic-carbapenem manufacturing facility.

Global Pharma | 04/01/2025 | By Abha |  445

Egypt to Establish USD 120 Million Pharmaceutical Hub in Suez Canal Economic Zone

The project will be located within SCZONE's Sokhna Integrated Industrial Zone and will span an area of 96,828 square meters.

Global Pharma | 04/01/2025 | By Abha |  1217

Karyopharm Welcomes Lori Macomber as its New Chief Financial Officer

Macomber has over 20 years of diversified experience in leading growth and driving financial strategies for life science companies.

Global Pharma | 03/01/2025 | By Aishwarya |  440

Shanghai MicuRx's MRX-5 Receives FDA Orphan Drug Designation for NTM Infections

MRX-5 is a novel benzoxazole antibiotic developed for treating mycobacteria infections, particularly infections caused by non-tuberculous mycobacteria (NTM).

Global Pharma | 03/01/2025 | By Abha |  636

Innovent's DOVBLERON Secures Second NMPA Approval for ROS1-Positive NSCLC

China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON®, a next-generation ROS1 tyrosine kinase inhibitor (TKI).

Global Pharma | 03/01/2025 | By Abha |  352

Veeda Group Announces Rebranding of its Identity as Veeda Lifesciences

Veeda Lifesciences represents the brand that integrates Veeda Clinical Research, Health Data Specialists, and Bioneeds India, showcasing research services across various stages of the drug development value chain from discovery and preclinical to late-phase development.

Global Pharma | 03/01/2025 | By Aishwarya |  641

CORXEL Signs Agreement with Sanofi for Aficamten in Greater China Markets

Aficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor discovered and developed globally by Cytokinetics.

Global Pharma | 02/01/2025 | By Aishwarya |  578

Lupin Acquires Huminsulin from Lilly to Strengthen Diabetes Portfolio

Lupin has acquired the Huminsulin range from Eli Lilly in India, strengthening its diabetes portfolio with treatments for type 1 and type 2 diabetes mellitus.

Global Pharma | 02/01/2025 | By Manvi |  274